United States Food and Drug Administration (USFDA) has concluded surveillance inspection at Shilpa Medicare's Unit VII, Analytical Services Division situated at IDA Mallapur, Nacharam, Uppal Mandal, Medchal, Malkajgiri, Hyderabad, Telangana. The inspection was conducted from September 16, 2026 to September 18, 2026. At the conclusion of the inspection, the USFDA issued one observation, which is procedural in nature.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
